23972-41-0

Usage

Uses

Used in Polymer Production:
2-Phenylmorpholine is used as a chemical intermediate in the production of certain types of polymers. Its unique structure allows it to be incorporated into the polymer chain, potentially enhancing the properties of the final product.
Used in Organic Synthesis:
2-Phenylmorpholine serves as an intermediate in various organic synthesis processes. Its presence in the reaction can lead to the formation of new compounds with different properties and applications, making it a valuable component in the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, 2-Phenylmorpholine's potential use in the pharmaceutical industry can be inferred due to its involvement in organic synthesis. It may be used as a building block for the development of new drugs or as a component in the synthesis of existing medications.
Used in Chemical Research:
2-Phenylmorpholine's unique structure and properties make it an interesting subject for chemical research. It can be used to study the effects of phenyl substitution on the properties of morpholine rings and to explore new reaction pathways and mechanisms in organic chemistry.

InChI:InChI=1/C10H13NO/c1-2-4-9(5-3-1)10-8-11-6-7-12-10/h1-5,10-11H,6-8H2

Upstream product

• 23980-75-8 4-benzyl-2-phenyl-morpholine 
• 74572-09-1 N-(2-hydroxyethyl)-N-(2-hydroxy-2-phenylethyl)amine 
• 100-42-5 styrene 
• 953986-10-2 4-((4-nitrophenyl)sulfonyl)-2-phenylmorpholine 
• 321977-41-7 2-phenyl-4-(toluene-4-sulfonyl)morpholine 
• 23980-35-0 [2-bromo-1-(2-chloro-ethoxy)-ethyl]-benzene 
• 108-86-1 bromobenzene 

Downstream Products

• 1134191-13-1 4-[2-(2-phenylmorpholin-4-yl)propyl]phenol 
• 1219624-65-3 1-[2-oxo-2-(2-phenylmorpholin-4-yl)ethyl]-3,3-diphenylpiperidin-2-one 
• 1145786-03-3 4-{6-[4-(4-methyl-1H-imidazol-1-yl)-3-(methyloxy)phenyl]-3-pyridazinyl}-2-phenylmorpholine 
• 152134-83-3 4-Amino-N-[1-(1H-benzimidazol-5-yl-methyl)-2-(2-phenylmorpholin-4-yl)-2-oxo-ethyl]-3,5-dichlorobenzenesulphonamide 

Relevant academic research and scientific papers

Catalyst-free and metal-free electrophilic bromoamidation of unactivated olefins using the N-bromosuccinimide/sulfonamide Protocol

An efficient, catalyst-free, and metal-free bromoamidation of unactivated olefins has been developed. 4-(Trifluoromethyl)benzenesulfonamide and N-bromosuccinimide were used as the nitrogen and halogen sources, respectively. The methodology is applicable to both cyclic and aliphatic olefins.

Facile, efficient, and catalyst-free electrophilic aminoalkoxylation of olefins: Scope and application

A new one-pot electrophilic aminoalkoxylation reaction using olefin, cyclic ether, amine, and N-bromosuccinimide has been developed. The olefinic substrates and the cyclic ether partners can be flexibly varied to produce a range of amino ether derivatives. This novel protocol has been applied in the facile and efficient synthesis of biologically active morpholine compounds.

Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as β3-adrenergic receptor agonists: Design, synthesis, biological evaluation and pharmacophore modeling

In search of potent β3-adrenergic receptor agonists, a series of novel substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes has been synthesized and evaluated for their β3-adrenergic receptor agonistic activity (ranging from -17.73% to 90.64% inhibition at 10 μM) using well established Human SK-N-MC neuroblastoma cells model. Four molecules viz. 11, 15, 22 and 23 showed β3-AR agonistic IC50 value of 0.55, 0.59, 1.18 and 1.76 μM, respectively. These four candidates have been identified as possible leads for further development of β3-adrenergic receptor agonists for obesity and Type-II diabetes pharmacotherapy. The free OH and NH functions are found to be essential for β3-adrenergic receptor agonistic activity. Among the synthesized β3-adrenergic receptor agonists having 1,2,3,4-tetrahydroquinoline scaffold, the N-benzyl group is found to be superior over N-arylsulfonyl group. A putative pharmacophore model has been modeled considering the above four active molecules which distinguishes well between the active and inactive molecules.

Steroidal anaesthetics of the pregnane and 19-norpregnane series

Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the steroids having a 3α-hydroxy group, a 17α-hydrogen atom, a 20-oxo group and at the 21-position a cyano, azido or basic amino group.